Once Daily Dose News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Once daily dose. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Once Daily Dose Today - Breaking & Trending Today

Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

– 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo – – 30 mg Once-Daily Dose of. ....

United States , Andreas Muehler , Jessica Breu , Daniel Vitt , Deprioritize Izumerogant , Edna Kaplan , Paula Schwartz , Exchange Commission , Rx Communications Group , Development Programs , Prnewswire Immunic Inc , Immunic Inc , Clinical Remission , Vidofludimus Calcium , Once Daily Dose , Endoscopic Healing , High Performing Vidofludimus Calcium , Immunic Decided , Conference Call , Chief Executive Officer , Chief Medical Officer , Eastern Europe , Private Securities Litigation Reform Act , Annual Report , Investor Relations ,

EQS-News: Immunic, Inc.: Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

Issuer: Immunic, Inc. / Key word(s): Study results/Strategic Company Decision Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe ....

United States , Paula Schwartz , Andreas Muehler , Deprioritize Izumerogant , Jessica Breu , Edna Kaplan , Daniel Vitt , Exchange Commission , Distribution Services , Strategic Company Decision , Development Programs , Immunic Inc , Rx Communications Group , Reports Positive Data , Maintenance Phase , Vidofludimus Calcium , Moderate To Severe Ulcerative Colitis , Moderate To Severe Ulcerative , Clinical Remission , Once Daily Dose , Endoscopic Healing , Focus Resources , High Performing Vidofludimus Calcium , Immunic Decided , Chief Executive Officer , Chief Medical Officer ,

EQS-News: Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

Issuer: Immunic, Inc. / Key word(s): Study results/Strategic Company Decision Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis 05.04.2023 / 12:30 CET/CEST The issuer is solely responsible for the cont. ....

United States , Daniel Vitt , Edna Kaplan , Jessica Breu , Andreas Muehler , Paula Schwartz , Deprioritize Izumerogant , Rx Communications Group , Exchange Commission , Strategic Company Decision , Distribution Services , Immunic Inc , Development Programs , Reports Positive Data , Maintenance Phase , Vidofludimus Calcium , Moderate To Severe Ulcerative Colitis , Moderate To Severe Ulcerative , Clinical Remission , Once Daily Dose , Endoscopic Healing , High Performing Vidofludimus Calcium , Immunic Decided , Conference Call , Chief Executive Officer , Chief Medical Officer ,

DGAP-News: Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection

(0)
DGAP-News: Immunic, Inc.
/ Key word(s): Study results
Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838 s Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection
15.04.2021 / 12:30
The issuer is solely responsible for the content of this announcement.
Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838 s Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection
- Preplanned Interim Analysis of 12-Week MRI Data from 10 mg IMU-838 Dose and Placebo, in Combination with Existing 30 and 45 mg Dose Data, Establishes Clear Dose-Response Relationship for IMU-838 -
- Totality of Data Clearly Supports Decision that 30 mg Once Daily Dose of IMU-838 Will Now Be Targeted for Phase 3 Development in Relapsing-Remitting Multiple Sclerosis - ....

United States , Edna Kaplan , Paula Schwartz , Jessica Breu , Andreas Muehler , Daniel Vitt , Program Expected To Start , Drug Administration , Rx Communications Group , Distribution Services , Exchange Commission , European Medicines Agency , Immunic Inc , Cohort Confirms , Relapsing Remitting Multiple Sclerosis , Supports Phase , Interim Analysis , Dose Data , Establishes Clear Dose Response Relationship , Data Clearly Supports Decision , Once Daily Dose , Now Be Targeted , Previously Announced , Second Half , Investigational New Drug , Chief Medical Officer ,